| High-grade serous | Low-grade serous | Mucinous | Clear cell | Endometrioid |
---|---|---|---|---|---|
Precursor lesion | Tubal intraepithelial carcinoma | Atypical serous borderline tumor | Metaplasia of transitional cells or metastasis from GI primary tumor* | Atypical Endometriosis | Atypical Endometriosis |
Histologic features | Positive: p16, CK7, WT-1, PAX-8, ER, CA125, E-cadherin (in most cases), p53 | Positive: PAX8, ER, WT-1, | Positive: CK7, PAX-8 (40%), p53 (30%) | Positive: CK7, PAX-8, HNF-1β | Positive: CK7, ER, PR, PAX-8 |
Negative: Her-2, calretinin, CK20 | Negative: p53 and p16 (negative, scattered or patchy) | Negative: WT-1, ER, PR and p16 | Negative: CK20, ER, WT-1, p53 and p16 (negative, weak, focal or patchy) | Negative: WT-1, p16, CK 20, p53 | |
Molecular aberrations | TP53 mutations | BRAF, KRAS, NRAS mutations | KRAS mutation | PTEN loss | PTEN loss |
BRCA1/2 mutations | HER2 amplification | PIK3CA mutation | PIK3CA mutation | ||
Chromosomal instability | ARID1A mutation | ARID1A mutation | |||
Risk factors | Inherited BRCA1/2 mutation | Â | Â | Endometriosis | Endometriosis |
Lynch syndrome |